Analysis of the sputum and inflammatory alterations of the airways in patients with common variable immunodeficiency and bronchiectasis by PEREIRA, Andrea Cristina et al.
1155
CLINICS 2009;64(12):1155-60
CLINICAL SCIENCE
I Pathology Department, Faculdade de Medicina da Universidade de São 
Paulo - São Paulo/SP, Brazil.
II
 Immunology Service, Hospital das Clinicas da Faculdade de Medicina da 
Universidade de São Paulo - São Paulo/SP, Brazil.
 
III
 Pulmonary Division, Heart Institute (Incor), Faculdade de Medicina da 
Universidade de São Paulo - São Paulo/SP, Brazil.
V Núcleo Avançado de Tórax, Hospital Sirio Libanês - São Paulo/SP, Brazil.
Email: andreacrisp03@terra.com.br
Tel.: 55 11 3064.2744 
Received for publication on July 23, 2009 
Accepted for publication on September 1, 2009 
ANALYSIS OF THE SPUTUM AND INFLAMMATORY 
ALTERATIONS OF THE AIRWAYS IN PATIENTS WITH 
COMMON VARIABLE IMMUNODEFICIENCY AND 
BRONCHIECTASIS
Andrea Cristina Pereira,I Cristina M. Kokron,II Beatriz Mangueira Saraiva 
Romagnolo,I Claudia Simeire Albertini Yagi,I Paulo Hilário Nascimento 
Saldiva,I Geraldo Lorenzi Filho,III Elnara Marcia Negri I ,V 
 
doi: 10.1590/S1807-59322009001200004
Pereira AC, Kokron CM, Saraiva-Romanholo BM, Albertini-Yagi CS, Lorenzi G, Negri EM. Analysis of the sputum and 
inflammatory alterations of the airways in patients with common variable immunodeficiency and bronchiectasis. Clinics. 
2009;64(12):1155-60.
INTRODUCTION: Common variable immunodeficiency is characterized by defective antibody production and recurrent pulmonary 
infections. Intravenous immunoglobulin is the treatment of choice, but the effects of Intravenous immunoglobulin on pulmonary 
defense mechanisms are poorly understood. 
OBJECTIVE: The aim of this study was to verify the impact of intravenous immunoglobulin on the physical properties of the sputum 
and on inflammatory alterations in the airways of patients with Common variable immunodeficiency associated with bronchiectasis. 
METHOD: The present study analyzed sputum physical properties, exhaled NO, inflammatory cells in the sputum, and IG titers 
in 7 patients with Common variable immunodeficiency and bronchiectasis with secretion, immediately before and 15 days after 
Intravenous immunoglobulin. A group of 6 patients with Common variable immunodeficiency and bronchiectasis but no sputum 
was also studied for comparison of the basal IgG level and blood count. The 13 patients were young (age=36±17 years) and com-
prised predominantly of females (n=11). 
RESULTS: Patients with secretion presented significantly decreased IgG and IgM levels. Intravenous immunoglobulin was associ-
ated with a significant decrease in exhaled NO (54.7 vs. 40.1 ppb, p<0.05), sputum inflammatory cell counts (28.7 vs. 14.6 cells/
mm3, p<0.05), and a significant increase in respiratory mucus transportability by cough (42.5 vs. 65.0 mm, p < 0.05). 
CONCLUSION: We concluded that immunoglobulin administration in Common variable immunodeficiency patients results in signifi-
cant improvement in indexes of inflammation of the airways with improvement in the transportability of the respiratory mucus by cough. 
KEYWORDS: IVIG; Airway inflammation; Pulmonary infection; Sputum; Pulmonary defense mechanisms.
INTRODUCTION
Common Variable Immunodeficiency (CVID) is an 
immunological disorder characterized by defective antibody 
production¹,² and recurrent infections, most notably of the 
respiratory tract. Recurrent pulmonary infections can lead to 
chronic diseases such as bronchiectasis and chronic air flow 
limitation; such conditions predispose patients to recurrent or 
prolonged infections, leading to bronchial wall inflammation 
and destruction of the respiratory epithelium.3,4
The respiratory epithelium continuously secretes and 
eliminates mucus that traps potentially noxious particles 
and microorganisms. Mucociliary clearance is one of the 
most important defense mechanisms of the airways. Efficient 
mucociliary clearance is essential for the maintenance 
of the integrity of the respiratory system and depends on 
interactions between cilia, mucus, and periciliary fluid. 
Impairment of the mucociliary clearance increases the 
risk of infection and inflammation.5-9 Previous studies of 
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bronchiectasic patients have shown marked alterations in 
mucus characteristics, including impairment in mucociliary 
transport,10 which may contribute to respiratory colonization 
and chronic inflammation. 
Intravenous immunoglobulin (IVIG) is a blood product 
prepared from the serum of 1000 to 15000 donors per batch. 
It is the treatment of choice for patients with antibody 
deficiencies.11 IVIG (400 mg/kg body weight) is considered 
as a standard treatment in patients with CVID. This therapy 
has been shown to substantially reduce the number of 
sinopulmonary infections.12 IVIG is typically given monthly 
and has been primarily used as an antibody replacement 
therapy, however, a number of other clinical benefits of IVIG 
have been demonstrated, including anti-inflammatory and 
immunomodulatory effects.13 To the best of our knowledge, 
the effects of IVIG on respiratory markers of inflammation 
or on mucus properties have not been previously studied.
The present study evaluated the impact of IVIG 
on sputum airway inflammation, as well as, on the “in 
vitro” mucus properties of patients with CVID-related 
bronchiectasis with secretion, just prior to and 15 days after 
IVIG therapy. In addition, hemogram and IG titers were 
compared between secretive and non-secretive patients with 
CVID. 
MATERIALS AND METHODS
For the present study we considered all patients with a 
diagnosis of CIVD associated with bronchiectasis who were 
followed regularly and were being treated once monthly with 
IVIG replacement at the Clinical Immunology and Allergy 
Division of the Hospital das Clínicas, Faculty of Medicine, 
University of São Paulo (HCFMUSP). CIVD was diagnosed 
by the presence of serum IgG and IgA levels that were two 
standard deviations below the average values for the patient’s 
age, a poor antibody response to vaccines, and the exclusion 
of other causes for hypogammaglobulinemia, as previously 
described1. Inclusion criteria also included the presence 
of bronchiectasis evidenced by computerized tomography 
(CT). To confirm the presence of bronchiectasis and CVID, 
the patients were thoroughly investigated using both CT 
examination and clinical criteria.14 Patients with evidence 
of acute respiratory infectious disease, as defined by fever, 
increased or altered aspects of respiratory secretion, and use 
of antibiotics over the 30 days before entry into or during 
the study period, were excluded from the study. All patients 
received all necessary information and signed a consent 
form that had been approved by the ethics committee of our 
Institution. Patients were divided according to the presence 
or absence of persistent sputum secretion. All patients were 
evaluated by hemogram and IG titers prior to the monthly 
gammaglobulin infusion. All patients with secretions were 
evaluated immediately before and 15 days after intravenous 
gammaglobulin infusion by each method described below. 
The IVIG was administered to these patient once a month, 
with an attack dose of 400 to 600 mg/kg of body weight and 
follow-up injections aimed at keeping the blood level of 
immunoglobulins above 400-500 mg/dL.
Exhaled Nitric Oxide (NO)
Exhaled NO was collected by a mouthpiece containing 
a 0.3 m3 bacterial HEPA filter (TROX Technik, Brazil).15 
Subjects were required to inhale orally up to their total lung 
capacity (TLC) through the mouthpiece attached to the 
sampling kit (Sievers Instruments Inc.). This kit contains 
a pressure gauge and an inspiratory filter that reduces the 
NO level from the inhaled air to a very low concentration. 
Once the subject had inhaled to TLC, a gentle exhalation 
maneuver was performed through the sampling kit to the 
Mylar bag without any breath holding (mean oral NO). The 
patient was instructed to achieve a breath pressure of 12 cm 
H20, monitored by the pressure gauge, which resulted in a 
flow rate of 200 ml/s. During this expiratory time, the patient 
was instructed to depress a stainless steel valve attached 
to the sampling kit after 3 seconds of exhalation and to 
continue for about 2 seconds, setting a collected volume 
larger than 50 ml (three samples). The breathing sample was 
collected into a NO-impermeable reservoir bag (Mylar bag; 
Sievers Instruments Inc.) with a volume capacity of 1.5 L. 
The bags were sealed and subsequently analyzed for ENO by 
chemiluminescence (Sievers model NOA 280).15
Sputum collection
Sputum samples were collected through induced cough 
with expectoration into a sterile plastic container. All 
collection procedures were supervised by the researchers. 
Some patients failed to present any secretion samples. 
Respiratory mucus was visually separated from saliva and 
divided into 3 aliquots. One aliquot was processed for the 
total cell count, as described below, one was spread over 
glass slides, air-dried, fixed, and stained with Leishman 
stain for the differential cell count, and one was stored in 
eppendorf tubes immersed in liquid vaseline oil in sealed 
plastic containers at – 70°C for the analysis of mucus 
transportability by cilia, cough, and contact angle, as 
described below. 
Total cell count in sputum
A phosphate-buffered saline solution was prepared 
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with dithiothreitol (DTT) [Sigma-Aldrich, Brazil] at 0.1% 
concentrations, added to an equal volume of sputum, and 
the mixture was briefly stirred using a vortex mixer. DTT 
is a sulfhydryl reagent that causes mucolysis by breaking 
disulfide bonds that crosslink glycoprotein fibers. The 
sample was treated with 0.1% DTT phosphate-buffered 
solution up to a ratio of 1:4 by volume. The mixture was 
then vortexed and rocked for 20 minutes at 37°C. The 
clear cell suspension was filtered through 48-µm nylon 
gauze (BBSH Thompsom; Scarborough, ON, Canada) 
to remove debris and mucus. Samples were processed as 
soon as possible (within 2 hours) after collection. Total cell 
counts were evaluated using a hemocytometer (Neubauer 
Chamber).16 
Differential cell count in sputum
The mucus sample was spread over glass slides, air-
dried, fixed, and stained with Leishman stain. A differential 
cell count was performed using a light microscope at 
1000X magnification.16 At least 200 cells were counted 
by two investigators who were blinded to the patient 
classification. Cells were classified as eosinophils, 
lymphocytes, neutrophils, or macrophages according to 
their morphology.17
In vitro mucociliary transport 
The frog palate is a convenient system for studying 
mucociliary transport, since the frog’s palate epithelium is 
similar to that of the airways of vertebrates. Anesthetized 
frogs were decapitated, their jaws disarticulated, and the 
upper portion of the head was removed. The frog palate 
was kept in a refrigerator at 4°C for two days covered 
with plastic wrap in a humidified chamber to deplete the 
frog mucus. Ciliary activity was maintained under these 
experimental conditions. The transport of a mucus sample 
placed upon a mucus-depleted frog palate was determined 
using a stereomicroscope equipped with a reticulated 
eyepiece. The velocity of the mucus sample to be tested was 
compared to the transport speed of autologous frog mucus, 
and the results are expressed in terms of the relative speed. 
In the experimental situation, the frog palate epithelium 
was considered to be ideal, with only its physical properties 
influencing mucus transport.18
Cough transportability
In healthy subjects, respiratory mucus is cleared from the 
lung by ciliary transport, but in various respiratory diseases 
such as chronic bronchitis, bronchiectasis, cystic fibrosis, 
and asthma, the secretion of mucus occurs in association 
with impairment of mucociliary transport. In this situation, 
cough clearance assumes a central role in eliminating 
secretions. 
In vitro cough experiments employ an apparatus called 
the “simulated cough machine” adapted from King et al., 
1985.19 A compressed air cylinder with a pressure gauge 
serves as a gas supply. Gas release is controlled by a 
solenoid valve at the outflow port of the cylinder. This is 
followed by an “upstream resistance”, which serves to make 
the flow-time profile of the simulated cough comparable to 
that of human coughing. Mucus transport is calculated by 
determining the displacement of mucus with the aid of a 
millimeter ruler.18
Contact Angle
The wettability of a biological fluid characterizes its 
ability to spread when deposited onto a solid planar surface. 
This spreading occurs because a finite interaction exists 
between the solid surface and the molecules present in the 
liquid. The degree of wettability is characterized by the 
contact angle between the tangent to the liquid-air interface 
and the surface.18 The contact angle is visualized using a 
25X magnification eyepiece with two movable arms (right 
and left, forward and backward). The eyepiece contains a 
goniometer with an angular scale of 0° to 180° that measures 
the angle between a mucus drop and the surface of a plate 
that has been treated with sulphochromic acid to remove 
the electric charges. A tempered-iron support with holes is 
placed under the plate, allowing humidification with vapor 
from a water bath kept at 37°C.18
Statistical Analyses
After descriptive analysis of the variables, the 
Kolmogorov-Smirnov test was used to assess the normal 
distributions of continuous variables. Differences among 
values were determined by the Student´s unpaired or 
paired t-test for independent comparisons or longitudinal 
observations of the same patients; the level of significance 
was p=0.05.
RESULTS
Thirty-five patients with a diagnosis of CVID associated 
with bronchiectasis who were regularly seen in the 
outpatient clinic were considered for the study; 18 of 
these patients were excluded because they did not agree to 
participate or had problems communicating. An additional 
4 patients were excluded due to acute respiratory infection 
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during the study period. Of the 13 patients studied, 7 
presented secretion and 6 patients presented no secretion. 
The demographic characteristics of the 13 patients with and 
without secretion are described in Table I.
In the patients that presented secretion, we found 
elevated exhaled NO (54.7 X 9.8 ppb), and these levels 
decreased significantly 15 days after IVIG infusion (40.1 
X 8.5 ppb) (Figure 1). Figure 2 shows the total number of 
mucus inflammatory cells present in these patients before 
and 15 days after IVIG infusion. Corroborating the results 
obtained by NO measurement, a marked decrease in the 
number of inflammatory cells was observed after IVIG 
infusion (p=0.016). A differential mucus inflammatory 
cell count was performed before and after intravenous 
immunoglobulin therapy. Although the total cell count 
was decreased after treatment, neutrophils remained the 
predominant cell type under both conditions (Figure 2B). 
We observed no significant change in ciliary mucus 
transportability before and after IVIG (0.96 ± 0.28 and 0.92 
± 0.39, respectively, p=0.796) or in the mucus contact angle 
(50 ± 9 and 45 ± 9°, respectively, p=0.303). A significant 
Table 1 - Demographic, clinical (time in IG therapy) and laboratorial characteristics (IG levels and differential leukocyte 
blood counts) of the 13 patients studied
Total of patients (n= 13) Secretive (n = 7) No Sputum (n=6) P
Age ( years) 36 ± 17 29 ± 12 43 ± 19 0.153
Gender, female (n) 11 6 5 -
BMI (Kg/m2) 19.9 ± 1.9 19.8 ± 2.3 19.9 ± 1.6 0.976
Time of IG therapy (years) 4.6 ± 6.2 6.2 ± 7.6 2.7 ± 3.6 0.234
IgG (mg/dL) 429.4 ± 1 312 ± 186 556 ± 127 0.024
IgA (mg/dL) 47 ± 118 8.7 ± 4.0 91.3 ± 171 0.295
IgM (mg/dL) 6.7 ± 7.3 3.1 ± 2.1 11 ± 9.1 0.048
Neutrophils/blood count (10³céls/mm³) 5 ± 2 5.1 ± 2.3 4.6 ± 1.4 0.651
Limphocytes/blood count (10³céls/mm³) 2.7 ± 2.9 3.32 ± 4 1.81 ± 0.36 0.945
Figure 1 - The exhaled NO levels immediately before and 15 days after 
IVIG in seven secretive patients with CVID associated to bronchiectasis. 
Note the decrease in NO levels after the treatment (p<0.05)
Figure 2 - Total inflammatory cell counts (A) and the differential cell 
counts (B) (Neu=neutrophils, Maf=macrophages, Ly=Lymphocytes and 
Eo=eosinophils) in sputum before and after intravenous immunoglobulin
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increase in cough transportability after IVIG was observed, 
as shown in Figure 3 (p=0.048). 
DISCUSSION
The present study showed that IVIG promotes a decrease 
in inflammation, as measured by decreases in exhaled NO 
and decreased numbers of mucus inflammatory cells, and 
is associated with an increase in mucus transportability 
by cough. These results suggest a correlation between 
inflammation and mucus physical properties, and this is, to 
our knowledge, the first study to address the importance of 
studying mucus properties in CVID. 
In CVID patients with bronchiectasis, immunoglobulin 
replacement is an important tool to avoid the progression of 
the disease, reducing infectious episodes. IVIG is used every 
3 to 4 weeks at a dose of 400 to 600 mg/kg of body weight; 
follow-up injections are aimed at keeping blood levels of 
immunoglobulins above 500 mg/dL.1,11,24-26 The mechanism 
of action of therapeutic immunoglobulin is complex. The 
objectives of immunoglobulin replacement are to diminish 
the frequency and severity of infectious episodes, to diminish 
the need for antibiotics, and to prevent the development 
of complications and sequelae. This treatment results in 
a reduction in the number of respiratory infections and a 
better quality of life for CVID patients.12,21,25 Nevertheless, 
its impact on the physical properties of mucus has not been 
previously addressed. 
Analysis of exhaled NO and total inflammatory cells 
in induced sputum in secretory patients showed a marked 
reduction in these inflammatory parameters after IVIG 
infusion. It is known that the cellularity of sputum does 
not directly reflect the number of inflammatory cells 
present in the distal lung parenchyma; the latter would 
be better estimated from bronchoalveolar lavage (BAL) 
samples. Nevertheless, induced sputum has the advantage 
of being a less invasive technique. BAL and induced 
sputum are “photographs” of different compartments 
within the respiratory system; however, as substrates for 
measuring respiratory system inflammation, they show 
a direct correlation.27,28 IVIG propitiated an increase in 
mucus transportability by cough, probably by influencing 
the amount of inflammatory cells present in mucus with 
a consequent reduction in the solid component of the 
respiratory secretions, facilitating mucus transport by 
cough.8 Cough is characterized by inhaling approximately 
two liters of air, with a fast glottal closure and an increase 
in pleural pressure to 100 cm H2O or more. With glottal 
opening, a biphasic air flow expulsion occurs with a fast 
initial component lasting approximately 30-50 ms followed 
by a slower component, which travels along the partially 
collapsed trachea. The expired gas reaches the mucus layer 
and transfers part of its kinetic energy, moving the mucus 
towards the glottis. The in vitro analysis of transportation 
by cough and sneeze using the cough simulator utilizes 
a compressed air reservoir, which predicts air flow and is 
controlled by a solenoid valve, followed by a resistance, 
which provides a turbulent flow similar to that of cough and 
sneeze.18
Though the present study demonstrated a reduction of 
exhaled NO in patients treated with IVIG; exhaled NO was 
not reduced to normal levels in these patients. NO values as 
well as neutrophil counts remained high after intravenous 
immunoglobulin infusion. This finding reinforces the 
importance of avoiding mucus stasis and emphasizes that 
cough is the main and most efficient mechanism of clearing 
bronchial secretion.
In our study, secretive patients presented lower levels 
of all immunoglobulins measured (IgG, IgM, and IgA) 
compared to the group of patients without secretion on 
the date of IVIG infusion. This observation represents “a 
picture” of an acute moment in the natural history of the 
disease in these patients and may indicate an important 
topic to address, since the maintenance of normal levels 
of Ig may, in some patients, require more frequent IVIG 
infusions. It is interesting to note that no difference in blood 
cell counts was observed between patients with and without 
secretion. In contrast, levels of NO were significantly higher 
in patients with secretion, suggesting that these patients have 
increased inflammation in the lungs. The pathophysiology 
of the pulmonary alterations in CVID is complex and 
multifactorial. As a result, a multicentered approach must 
be taken in order to reduce the occurrence of bronchiectasis 
and the consequent loss of pulmonary function in these 
patients. Studies of inflammatory modulation and the 
physical properties of mucus in CVID can supply necessary 
information and help to improve treatment strategies for this 
disease.
Figure 3 - Cough transportability data distribution before and after immu-
noglobulin infusion in these seven patients with secretion (p<0,05)
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CONCLUSION
Intravenous immunoglobulin therapy resulted in 
an improvement in inflammation of the airways fifteen 
days after infusion, reflecting an improvement of the 
transportability of mucus by cough and persistent secretion 
that was associated with lower levels of IgG among patients 
with CVID under IVIG.
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